Well, the U.S. just established a new AI safety review office in the department of commerce, and this might help with ...

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

The ongoing debate about India and Pakistan playing on each other's soil has given rise to a new term in cricket: The 'hybrid ...

President of Serbia, Aleksandar Vučić, spoke today with the representatives of Matica Srpska and the manager of the Matica ...

In 2024, “rawdogging” may have referred to (select all that apply): Only eating uncooked meat. Sexual intercourse without a ...

With terms like "skibidi," "demure" and "rizz" rising in popularity, 2024 has marked a new, if strange, phase of the English ...

In a report released today, Joseph Stringer from Needham maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report). The ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.5, a high estimate of $10.00, ...

As recently as last month, Lexicon Pharmaceuticals Inc. was holding out hope regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

This is self-inflicted marginalization. The conception of the basis of Nigerian nation-state and of its democratic system, ...

H.C. Wainwright has recently initiated Lexicon Pharmaceuticals Inc (LXRX) stock to Buy rating, as announced on June 17, 2024, according to Finviz. Earlier, on April 30, 2024, Leerink Partners had ...

Lexicon Pharmaceuticals received a complete response letter from the Food and Drug Administration for its treatment of type 1 diabetes and chronic kidney disease. The FDA's response, which according ...